ClinicalTrials.gg
RecruitingNCT07436039Updated Feb 27, 2026

Color Change and Desensitization of Molar Incisor Hypomineralization-Affected Enamel Using Biomimetic Nano-Hydroxyapatite Toothpaste

An interventional study of Fluoridated Toothpaste and Nano-hydroxyapatite Toothpaste in Molar-Incisor Hypomineralization (MIH), sponsored by King Abdulaziz University. Recruiting at 1 site in Saudi Arabia. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by King Abdulaziz University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

This clinical trial aims to evaluate if nano-hydroxyapatite (Nano-HA) toothpaste effectively treats children with Molar-Incisor Hypomineralization (MIH). It will also assess the safety of Nano-HA toothpaste. The main questions are:

  • Does Nano-HA toothpaste reduce caries incidence, improve tooth aesthetics, and decrease hypersensitivity?
  • How does Nano-HA compare to fluoridated toothpaste in terms of outcomes?

Participants will:

  • Use Nano-HA or fluoridated toothpaste daily for 12 months.
  • Visit the clinic for checkups and evaluations every 1 to 3 months.
  • Record symptoms, brushing compliance, and sensitivity.

The study will compare Nano-HA toothpaste to fluoridated toothpaste to determine its efficacy in managing MIH .

02

Conditions studied

  • Molar-Incisor Hypomineralization (MIH)
03

In context

Molar Hypomineralization

133 studies on the registry are indexed under Molar Hypomineralization; 46 are open to participants now.

This study's planned enrollment of 60 is above the median of 53 across 104 interventional studies indexed under Molar Hypomineralization.

Browse Molar Hypomineralization studies →

Lead sponsor

King Abdulaziz University is the lead sponsor of 98 studies on the registry; 19 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Children aged 6-12 years.

  • Diagnosed with Molar-Incisor Hypomineralization (MIH) in at least one first permanent molar or hypomineralization of a second primary molar (HSPM).
  • Presence of white, creamy, yellow, or brown demarcated opacities
  • Indexed teeth include permanent first molars and permanent maxillary incisors.

Exclusion criteria

Exclusion Criteria:

    • Decayed permanent molars.

      • Diabetes, hypertension, sleeping disorders, or allergic reactions to medications.
      • Children on medication
      • Presence of other enamel defects (e.g., fluorosis, amelogenesis imperfecta, enamel hypoplasia, or white spot lesions).
      • Previous treatment with liquid enamel or other remineralizing agents on affected teeth.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Nano-hydroxyapatite Toothpaste Group

    Participants in this group will use Nano-hydroxyapatite toothpaste for 9 months to assess its effect on reducing caries, improving aesthetics, and decreasing sensitivity.

    Device: Nano-hydroxyapatite Toothpaste

  • Active comparator
    Fluoridated Toothpaste Group

    Participants in this group will use fluoridated toothpaste (1450 ppm fluoride) three times daily under parental supervision for 9 months.

    Device: Fluoridated Toothpaste

Interventions

  • DeviceFluoridated Toothpaste

    Participants will use fluoridated toothpaste (1450 ppm fluoride) three times daily under parental supervision for 9 months to compare its effects with Nano-hydroxyapatite.

  • DeviceNano-hydroxyapatite Toothpaste

    Participants in this group will brush their teeth with Nano-hydroxyapatite toothpaste three times daily under parental supervision for 9 months to evaluate its impact on caries reduction, aesthetics, and sensitivity.

06

What researchers measure

Primary outcomes

  1. Desensitization of Molar Incisor Hypomineralization-Affected Enamel Using Biomimetic Nano-Hydroxyapatite Toothpaste

    Hypersensitivity can be measured using the Schiff sensitivity scale to rate patients' pain The Schiff Cold Air Sensitivity Scale is a 4-point scale used to assess dentin hypersensitivity. A score of zero indicates no sensitivity, one signifies mild sensitivity without a request to stop the stimulus, two represents moderate sensitivity with a request to stop or visible discomfort, and three indicates severe sensitivity with a request to stop and physical withdrawal.

    Time frame: Follow-up duration: 12 months. Clinical evaluations will be conducted at baseline (T0), 1 month (T1), 3 months (T2), 6 months (T3), 9 months (T4), and 12 months (T5). The primary endpoint will be assessed at 6 months to evaluate treatment effectiveness

Secondary outcomes

  1. Color Change of Molar Incisor Hypomineralization-Affected Enamel Using Biomimetic Nano-Hydroxyapatite Toothpaste

    The VITA Easyshade® advance spectrophotometer (VITA Zahnfabrik, Bad Sackingen, Germany) will be used to assess the color of MIH-affected permanent incisors and the adjacent sound enamel

    Time frame: 12 months (Evaluations will be conducted at follow-up intervals: 1 month, 3 months, 6 months, 9 months and 12 months after the trial starts).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 62 non-industry interventional studies with no phase under Molar Hypomineralization, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's planned 20 months is above that.

Counting every sponsor, half of 62 studies reached it within 14 months; a quarter within 8 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2025
First posted
Feb 27, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07436039
Lead sponsor
King Abdulaziz University
Responsible party
Heba sabbagh (Principal Investigator, King Abdulaziz University) — Principal investigator
First posted
Feb 27, 2026
Start date
Oct 1, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

sabbagh
Contact
hjsabbagh@gmail.com
+966 50 566 8481

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion